Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics of the included cohorts

From: Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab

Characteristics Cohort I Cohort II Cohort III (rituximab)
  Number = 32 Number = 182 Number = 40
Demographics    
Age, years 49 ± 10 54 ± 12 57 ± 10
Female, number (%) 22 (69) 135 (75) 34 (85)
Disease characteristics    
Disease duration, years 7.5 ± 8.9 9.5 ± 10.2 11.0 ± 9.5
Disease activity (DAS28) 5.4 ± 1.3 5.1 ± 1.2 5.8 ± 1.1
ESR, mm/hour 29.3 ± 22.2 24.5 ± 18.0 29.2 ± 23.8
CRP, mg/L 18.8 ± 19.4a 17.8 ± 22.1 17.7 ± 17.7
Erosions, number (%) 24 (75) 131 (72) 28 (72)
IgM RF positive, number (%) 28 (88) 130 (71) 27 (68)
ACPA positive, number (%) 26 (87)b 129 (75)c 29 (73)
Medication    
Current prednisone use, number (%) 6 (19) 52 (29) 27 (68)
Prednisone dosage, mg/day 8 ± 2 7.2 ± 3.5 6.75 ± 6.0
Current MTX use, number (%) 25 (78) 152 (84) 26 (65)
MTX dosage, mg/week 21.2 ± 7.1 21.0 ± 6.3 18.7 ± 8.2
Current SSZ use, number (%) N/A 27 (16)d 7 (18)
Current HCQ use, number (%) N/A 35 (20)d 5 (13)
  1. aData missing for 7 of the 32 patients; bdata missing for 2 of the 32 patients; cdata missing for 9 of the 182 patients; ddata missing for 9 of the 182 patients. Continuous variables are presented as mean with standard deviation. ACPA, anti-cyclic citrullinated protein antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; MTX, methotrexate; N/A, not applicable;RF, rheumatoid factor; SSZ, sulphasalazine.